Anika Therapeutics (ANIK) Consolidated Net Income (2016 - 2025)
Historic Consolidated Net Income for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $846000.0.
- Anika Therapeutics' Consolidated Net Income rose 10301.36% to $846000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 5650.33%. This contributed to the annual value of -$47.6 million for FY2024, which is 3997.45% up from last year.
- Latest data reveals that Anika Therapeutics reported Consolidated Net Income of $846000.0 as of Q3 2025, which was up 10301.36% from $677000.0 recorded in Q2 2025.
- Anika Therapeutics' Consolidated Net Income's 5-year high stood at $16.2 million during Q4 2023, with a 5-year trough of -$28.1 million in Q3 2024.
- In the last 5 years, Anika Therapeutics' Consolidated Net Income had a median value of -$2.6 million in 2024 and averaged -$2.3 million.
- The largest annual percentage gain for Anika Therapeutics' Consolidated Net Income in the last 5 years was 41137.91% (2022), contrasted with its biggest fall of 85398.55% (2022).
- Anika Therapeutics' Consolidated Net Income (Quarter) stood at -$3.2 million in 2021, then soared by 411.38% to $10.1 million in 2022, then soared by 60.71% to $16.2 million in 2023, then crashed by 219.74% to -$19.4 million in 2024, then soared by 104.37% to $846000.0 in 2025.
- Its Consolidated Net Income stands at $846000.0 for Q3 2025, versus $677000.0 for Q2 2025 and -$915000.0 for Q1 2025.